GlassScriptPhysician profile
Mark R Neustrom
NPI 1063449288
$3,499.21
in general payments reported to CMS, 2019-2025
23 companies · $588 in 2025
The $588 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $1,174 · 2021: $53.39 · 2022: $129 · 2023: $15.45 · 2024: $598 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,416.43 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Shire North American Group INC | $900.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $154.62 | 2022-2025 | Fasenra |
| Glaxosmithkline, LLC. | $152.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Hospira, INC. | $131.22 | 2022-2024 | |
| Ionis Pharmaceuticals, INC. | $124.31 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $113.06 | 2024-2025 | Orladeyo |
| Pharming Healthcare, INC. | $72.00 | 2024-2025 | Ruconest |
| Csl Behring | $60.66 | 2024-2025 | Haegarda, Hizentra |
| Grifols USA, LLC | $52.36 | 2020-2024 | Xembify |
| Pfizer INC. | $49.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $49.11 | 2024-2025 | Dupixent |
| Cycle Pharmaceuticals INC | $34.78 | 2024-2025 | Sajazir |
| Genentech USA, INC. | $31.53 | 2019-2025 | Xolair |
| Abbvie INC. | $27.91 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.97 | 2025 | Ebglyss |
| Optinose US, INC. | $23.88 | 2024 | |
| Amgen INC. | $20.68 | 2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $16.33 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $15.33 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $15.10 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Neustrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.